1. Home
  2. KOPN vs TRDA Comparison

KOPN vs TRDA Comparison

Compare KOPN & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$2.93

Market Cap

396.8M

Sector

Technology

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$13.81

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOPN
TRDA
Founded
1984
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.8M
481.6M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
KOPN
TRDA
Price
$2.93
$13.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$4.25
$21.00
AVG Volume (30 Days)
3.5M
158.9K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
103.03
N/A
EPS
0.01
N/A
Revenue
$1,530,311.00
$25,421,000.00
Revenue This Year
$50.07
$39.97
Revenue Next Year
$33.33
$50.80
P/E Ratio
$272.00
N/A
Revenue Growth
46.53
N/A
52 Week Low
$0.88
$4.93
52 Week High
$4.16
$14.49

Technical Indicators

Market Signals
Indicator
KOPN
TRDA
Relative Strength Index (RSI) 66.18 59.80
Support Level $2.24 $10.84
Resistance Level $3.28 $13.99
Average True Range (ATR) 0.26 0.74
MACD 0.07 0.09
Stochastic Oscillator 96.19 81.62

Price Performance

Historical Comparison
KOPN
TRDA

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: